Novel liposomal Doxorubicin formulation for the treatment of advanced metastatic solid tumors
F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers
MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.
